Sara Lo Menzo
Overview
Explore the profile of Sara Lo Menzo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
69
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mengato D, Mazzitelli M, Francavilla A, Bettio M, Sasset L, Presa N, et al.
Clin Exp Med
. 2023 Jun;
23(6):2757.
PMID: 37289236
No abstract available.
2.
Mazzitelli M, Gregori D, Sasset L, Trevenzoli M, Scaglione V, Menzo S, et al.
Microorganisms
. 2023 Apr;
11(4).
PMID: 37110408
Background: A large increase in multi-drug-resistant , especially carbapenem-resistant strains, occurred during the first two years of the COVID-19 pandemic, posing important challenges in its treatment. Cefiderocol appeared to be...
3.
Mengato D, Mazzitelli M, Francavilla A, Bettio M, Sasset L, Presa N, et al.
Clin Exp Med
. 2023 Mar;
23(6):2749-2756.
PMID: 36961678
Since the beginning of Coronavirus Disease 2019 (COVID-19) pandemic, many drugs have been purposed for the treatment of severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2). Remdesivir emerged as an encouraging antiviral drug...
4.
Mazzitelli M, Trunfio M, Putaggio C, Sasset L, Leoni D, Menzo S, et al.
Biomedicines
. 2022 Aug;
10(8).
PMID: 36009370
To date, therapeutic switches are performed to reduce and prevent toxicity, improve adherence, promote virological control, and save costs. Drug switches are a daily challenge in the management of people...
5.
Longato E, Morieri M, Sparacino G, Di Camillo B, Cattelan A, Menzo S, et al.
Comput Methods Programs Biomed
. 2022 May;
221:106873.
PMID: 35588662
Background And Objective: COVID-19 severity spans an entire clinical spectrum from asymptomatic to fatal. Most patients who require in-hospital care are admitted to non-intensive wards, but their clinical conditions can...
6.
Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Menzo S, et al.
Viruses
. 2022 Mar;
14(3).
PMID: 35336900
SARS-CoV-2 can produce both severe clinical conditions and long-term sequelae, but data describing post-acute COVID-19 syndrome (PACS) are lacking for people living with HIV (PLWH). We aimed at assessing the...
7.
Menzo S, Marinello S, Biasin M, Terregino C, Franchin E, Crisanti A, et al.
Infection
. 2021 Apr;
49(6):1341-1345.
PMID: 33840038
Purpose: We report on the first identified cluster of the B.1.1.7 variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in the northeast of Italy. Methods: The cluster was...
8.
Menzo S, Biagi E, Di Nuzzo M, Grilli A, Contini C
Ann Hepatol
. 2018 Jun;
17(4):661-664.
PMID: 29893709
Directly-acting antivirals (DAA) have changed the chronic hepatitis C virus (HCV) infection therapeutic scenario allowing virus eradication in more than 95% of patients, independently from the genotype, with 12 to...
9.
Iannetta M, Zingaropoli M, Bellizzi A, Morreale M, Pontecorvo S, DAbramo A, et al.
PLoS One
. 2016 Aug;
11(8):e0160277.
PMID: 27486658
The anti-CD49d monoclonal antibody natalizumab is currently an effective therapy against the relapsing-remitting form of multiple sclerosis (RRMS). Natalizumab therapeutic efficacy is limited by the reactivation of the John Cunningham...
10.
Menzo S, la Martire G, Ceccarelli G, Venditti M
Mediterr J Hematol Infect Dis
. 2015 Jul;
7(1):e2015044.
PMID: 26185609
Bloodstream infections (BSI) are a significant cause of morbidity and mortality in onco-hematologic patients. The Gram-negative bacteria were the main responsible for the febrile neutropenia in the sixties; their impact...